Catapres-TTS en es it fr

Catapres-TTS Brand names, Catapres-TTS Analogs

Catapres-TTS Brand Names Mixture

  • Combipres 0.1/15 Tab (Chlorthalidone + Clonidine Hydrochloride)

Catapres-TTS Chemical_Formula


Catapres-TTS RX_link

Catapres-TTS fda sheet

Catapres-TTS msds (material safety sheet)

Catapres-TTS MSDS

Catapres-TTS Synthesis Reference

Zeile et al.; U.S. Pat. 3,202,660(1965)

Catapres-TTS Molecular Weight

230.093 g/mol

Catapres-TTS Melting Point


Catapres-TTS H2O Solubility


Catapres-TTS State


Catapres-TTS LogP


Catapres-TTS Dosage Forms

Tablet; Patch

Catapres-TTS Indication

For the treatment of hypertension and maybe used in prophylaxis of migraine or recurrent vascular headache; Menopausal flushing

Catapres-TTS Pharmacology

Clonidine is an antihypertensive agent and an epidural agent for refractory cancer pain. Similar to guanabenz in mechanism of action, clonidine is used in the treatment of hypertension, opiate and nicotine withdrawal, vascular headaches, diabetic diarrhea, glaucoma, ulcerative colitis, Gilles de la Tourette's syndrome, menopause symptoms, severe pain in cancer patients refractory to opiate agonists, and neuropathic pain and in the diagnosis of pheochromocytoma.

Catapres-TTS Absorption

Well absorbed following oral administration. Bioavailability following chronic administration is approximately 65%.

Catapres-TTS side effects and Toxicity

Oral LD50 is 150 mg/kg in rat and 30 mg/kg in dog. Symptoms of overdose include constriction of pupils of the eye, drowsiness, high blood pressure followed by a drop in pressure, irritability, low body temperature, slowed breathing, slowed heartbeat, slowed reflexes, and weakness.

Catapres-TTS Patient Information


Patients who engage in potentially hazardous activities, such as operating machinery or driving, should be advised of a potential sedative effect of clonidine. Patients should be cautioned against interruption of clonidine hydrochloride therapy without a physician's advice.

Epidural Injection

Patients should be instructed about the risks of rebound hypertension and warned not to discontinue clonidine except under the supervision of a physician. Patients should notify their physician immediately if clonidine administration is inadvertently interrupted for any reason. Patients who engage in potentially hazardous activities, such as operating machinery or driving, should be advised of the potential sedative and hypotensive effects of epidural clonidine. They should also be informed that sedative effects may be increased by CNS-depressing drugs such as alcohol and barbiturates, and that hypotensive effects may be increased by opiates.

Catapres-TTS Organisms Affected

Humans and other mammals